BioMarin Pharmaceutical Inc. has launched the syndication of a new $2 billion senior secured term loan B facility in connection with its pending acquisition of Amicus Therapeutics, Inc. This new facility is in addition to an $800 million senior secured term loan A facility and a $600 million senior secured revolving credit facility that BioMarin expects to enter into as part of the acquisition. The company also plans to offer $850 million of senior unsecured notes due 2034, with proceeds, along with borrowings under the new credit facilities and cash on hand, intended to fund the acquisition consideration and related expenses.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioMarin Pharmaceutical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-021718), on January 26, 2026, and is solely responsible for the information contained therein.